Table 2.
Frequencies of IgA antibody responders a against LTB and CF antigens in ALS and plasma specimens from ETEC patients.
| Day 2 | Day 7 | P-value b | Day 30 | P-value b | Day 90 | P-value b | Cumulative (Day 2/7/30/90) |
|
|---|---|---|---|---|---|---|---|---|
| ALS | ||||||||
| LTB | 3/26 (12%) | 14/25 (56%) | 0.001 | 1/20 (5%) | 0.622 | – | – | 14/26 (54%) |
| CS6 | 1/12 (8%) | 11/12 (92%) | <0.001 | 1/10 (10%) | 1.000 | – | – | 11/12 (92%) |
| CS5 | 0/11 (0%) | 9/11 (82%) | <0.001 | 2/9 (22%) | 0.190 | – | – | 9/11 (82%) |
| CFA/I | 2/6 (33%) | 6/6 (100%) | 0.061 | 3/5 (60%) | 0.567 | – | – | 6/6 (100%) |
| Plasma | ||||||||
| LTB | 4/26 (15%) | 17/25 (68%) | <0.001 | 10/22 (45%) | 0.029 | 4/19 (21%) | 0.704 | 17/26 (65%) |
| CS6 | 0/12 (0%) | 10/12 (83%) | <0.001 | 2/10 (20%) | 0.195 | 0/8 (0%) | 1.000 | 10/12 83%) |
| CS5 | 0/11 (0%) | 8/11 (73%) | 0.001 | 2/9 (22%) | 0.190 | 0/7 (0%) | 1.000 | 8/11 (73%) |
| CFA/I | 1/6 (17%) | 4/6 (67%) | 0.242 | 2/5 (40%) | 0.546 | 1/3 (33%) | 1.000 | 4/6 (67%) |
a
A responder was defined as having ≥2-fold higher antibody titer compared to the mean+2SD titer of the group of healthy controls.
b
Statistical analysis was performed using the Fisher’s Exact test to compare the responder frequency between day 7, 30 and 90 vs day 2.